Role of aldosterone in the remnant kidney model in the rat

Journal of Clinical Investigation

Volumn 98, Issue 4, 1996, Pages 1063-1068

  Greene, E L ^a,c   Kren, S ^a   Hostetter, T H ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

aldosterone; glomerulus; hypertension; renal failure; renin

Indexed keywords

ALDOSTERONE; ENALAPRIL; LOSARTAN; SPIRONOLACTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; GLOMERULOSCLEROSIS; HYPERALDOSTERONISM; HYPERTENSION; KIDNEY INJURY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0029810416     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118867     Document Type: Article

References (34)

1. Rosenberg, M.E., L.J. Smith, R. Correa-Rotter, and T.H. Hostetter, 1994. The paradox of the renin-angiotensin system in chronic renal disease. Kidney Int. 45:403-410.
2. Anderson, S., H.G. Rennke, and B.M. Brenner, 1986. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J. Clin. Invest. 77:1993-2000.
3. Lafayette, R.A., G. Mayer, S.K. Park, and T.W. Meyer. 1992. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J. Clin. Invest. 90:766-771.
4. Lewis, E.J., L.G. Hunsicker, R.P. Bain, and R.D. Rohde. 1993. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N. Engl. J. Med. 324:1456-1462.
5. Martin, R.S., W.J. Jones, and J.P. Hayslett. 1983. Animal model to study the effect of adrenal hormones on epithelial function. Kidney Int. 24:386-391.
6. Baba, K., Y. Doi, R. Franco-Saenz, and P.J. Mulrow. 1986. Mechanisms by which nephrectomy stimulates adrenal renin. Hypertension (Dallas). 8:997-1002.
7. Morrison, A.B. 1962. Experimentally induced chronic renal insufficiency in the rat. Lab. Invest. 11:321-331.
8. Hené, R.J., P. Boer, H.A. Koomans, and E.J.D. Mees. 1982. Plasma aldosterone concentrations in chronic renal disease. Kidney Int. 21:98-101.
9. Berl, T., F.H. Katz, W.L. Henrich, A. de Torrente, and R.W. Schrier. 1978. Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure. Kidney Int. 14:228-235.
10. Reams, G.P., and J.H. Bauer. 1986. Effect of enalapril in subjects with hypertension associated with moderate to severe renal dysfunction. Arch. Intern. Med. 146:2145-2148.
11. Williams, G.H., and R.G. Dluhy. 1987. Diseases of the adrenal cortex. In Harrison's Principles of Internal Medicine. 11th Edition. E. Braunwald, K.J. Isselbacher, R.G. Petersdorf, J.D. Wilson, J.D. Martin, and A.S. Fauci, editors. McGraw-Hill, New York. 1753-1775.
12. Walker, W.G. 1993. Hypertension-related renal injury: a major contributor to end-stage renal disease. Am. J. Kidney Dis. 22:164-173.
13. Quan, Z.Y., M. Walser, and G.S. Hill. 1992. Adrenalectomy ameliorates ablative nephropathy in the rat independently of corticosterone maintenance level. Kidney Int. 41:326-333.
14. Purkerson, M.L., P.E. Hoffsten, and S. Klahr. 1976. Pathogenesis of the glomerulopathy associated with renal infarction in rats. Kidney Int. 9:407-417.
15. Purkerson, M.L., D.M. Tollefsen, and S. Klahr. 1988. N-desulfated/acetylated heparin ameliorates the progression of renal disease in rats with subtotal renal ablation. J. Clin. Invest. 81:69-74.
16. Olson, J.L. 1984. Role of heparin as a protective agent following reduction of renal mass. Kidney Int. 25:376-382.
17. Ruilope, L.M., B. Miranda, J.M. Morales, J.L. Rodicio, J.C. Romero, and L. Raij. 1989. Converting enzyme inhibition in chronic renal failure. Am. J. Kidney Dis. 13:120-126.
18. Pitt, B. 1995. "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy. Cardiovas. Drugs Ther. 9:145-149.
19. Brilla, C.G., and K.T. Weber. 1992. Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J. Lab. Clin. Med. 120:893-901.
20. Young, M., M. Fullerton, R. Dilley, and J. Funder. 1994. Mineralocorticoids, hypertension and cardiac fibrosis. J. Clin. Invest. 93:2578-2583.
21. Cowley, A.W. 1992. Long-term control of arterial blood pressure. Physiol. Rev. 72:231-278.
22. Onoyama, K., E.L. Bravo, and R.C. Tarazi. 1979. Sodium, extracellular fluid volume, and cardiac output changes in the genesis of mineralocorticoid hypertension in the intact dog. Hypertension (Dallas). 1:331-336.
23. Pan, Y., and D.B. Young. 1982. Experimental aldosterone hypertension in the dog. Hypertension (Dallas). 4:279-287.
24. Daniels, B.S., and T.H. Hostetter. 1990. Adverse effects of growth in the glomerular circulation. Am. J. Physiol. 258:F1409-F1416.
25. Lax, D.S., J.A. Benstein, E. Tolbert, and L.D. Dworkin. 1992. Effects of salt restriction on renal growth and glomerular injury in rats with remnant kidneys. Kidney Int. 41:1527-1534.
26. Smith, J.M., and A.W. Jones. 1990. Calcium antagonists inhibit elevated potassium efflux from aorta of aldosterone-salt hypertensive rats. Hypertension (Dallas). 15:78-83.
27. Wang, W. 1994. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension (Dallas). 24:571-575.
28. Lariviere, R., G. Thibault, and E.L. Schiffrin. 1993. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate - salt hypertensive but not in spontaneously hypertensive rats. Hypertension (Dallas). 21:294-300.
29. Ullian, M.E., J.R. Schelling, and S.L. Linas. 1992. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension (Dallas). 20:67-73.
30. Dworkin, L.D., T.H, Hostetter, H.G. Rennke, and B.M. Brenner. 1984. Hemodynamic basis for glomerular injury in rats with desoxycorticosterone salt hypertension. J. Clin. Invest. 73:1448-1461.
31. Wakisaka, M., M.J. Spiro, and R.G. Spiro. 1994. Synthesis of type VI collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IV collagen. Diabetes. 43:95-103.
32. Todd-Turla, K.M., J. Schnermann, G. Fejes-Toth, A. Naray-Fejes-Toth, A. Smart, P.D. Killen, and J.P. Briggs. 1993. Distribution of mineralocorticoid and glucocorticoid receptors mRNA along the nephron. Am. J. Physiol. 264: F781-F791.
33. Wehling, M., M. Christ, and K. Theisen. 1992. Membrane receptors for aldosterone: a novel pathway for mineralocorticoid action. Am. J. Physiol. 263: E974-E979.
34. Wehling, M., J. Kasmayr, and K. Tikerson. 1991. Rapid effects of mineralocorticoids on sodium-proton exchanger: genomic or nongenomic pathway? Am. J. Physiol 260 (Endocrine Metab 23):E719-E726.